Product imageResearch use only

CAT. NO. DC68057Featured

Lipid Trp-L1-T4

Research highlights

Tfh-cell-competent saRNA deliveryCXCR5-targeted CAR-Tfh researchSustained CAR and Foxp3 expressionPreclinical autoimmune-hepatitis model

Pack size & price

USD

Add the cited formulation componentsSelected Lipid Trp-L1-T4 pack + every supporting component at 100 mg each+US$450 / set

Supporting components

Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg+DOPE DC33634 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

TotalUS$750

We match the best price and quality on market.

Ships from ShanghaiIce-pack transportPure lipid recommended

Product overview

Description & Application

Trp-L1-T4 is a novel tryptophan-derived ionizable lipid that serves as the core functional component of the optimized lipid nanoparticle (TLNP/RLNP) platform. Its primary function is to enable the efficient encapsulation and in vivo delivery of self-amplifying RNA (saRNA) cargo. Specifically, it facilitates high transfection efficiency and cytosolic release of the RNA payload in target follicular helper T (Tfh) cells, with minimal cytotoxicity. This capability is crucial for reprogramming pathogenic Tfh cells into regulatory CAR-Tfh cells, forming the foundation of the study's therapeutic strategy.

CAS No.	Not available
Chemical Name	Lipid Trp-L1-T4
Synonyms	Trp-L1-T4, Trp L1 T4, Trp-L1T4, TLNP ionizable lipid
SMILES	CCCCCCCCCCCCCCN(CCCCCCCCCCCCCC)CCNC(=O)[C@@H](N)Cc1c[nH]c2ccccc12
Formula	C41H74N4O
M.Wt	639.07
Purity	>95% by ELSD-HPLC
Storage	Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping condition	Ships from Shanghai. Pure lipid is stable during ice-pack transport.
Publication	Zheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604.

Literature-reported formulation composition

Component	Reported molar ratio	Role
Trp-L1-T4	25	Ionizable lipid
Cholesterol	20	Sterol
DMG-PEG2000	0.5	PEG lipid
DOPE	10	Helper phospholipid
Reported ratio sum	55.5	Original ratio retained

Component molecular weights and calculated amounts

Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.

Total lipid mass (mg)

Component	Normalized mol%	Amount (µmol)	Weight (mg)
Trp-L1-T4	45.045	77.1520	49.3056
Cholesterol	36.036	61.7216	23.8647
DMG-PEG2000	0.901	1.5430	3.8684
DOPE	18.018	30.8608	22.9614

Calculated total: 100.0000 mg lipid.

Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.

N/P ratioNot reported in the cited article

Total lipid:cargo weight ratio10:1 ionizable lipid:saRNA (w/w) in the main text; Supplementary Figure S1D labels the optimized axis as total lipids:mRNA, creating a terminology ambiguity

Buffer & pH10 mM citrate aqueous phase, pH 3; post-mixing dialysis against PBS

CargoGFP self-amplifying RNA (saRNA)

Administration routeIn vitro Tfh-cell transfection for the lead TLNP result; targeted therapeutic variants were given intravenously

Dose80 ng GFP-saRNA per 50,000 Tfh cells

Animal modelPrimary mouse follicular helper T cells for lead screening

Formulation processStaggered-herringbone microfluidic mixing at 3:1 aqueous:ethanol flow-rate ratio; 2 h dialysis through a 10 kDa membrane, concentration with a 100 kDa filter and 0.22-micrometer filtration; stored at 4 degrees C.

Literature-reported performance for the cited formulation

Literature-reportedGFP-positive primary Tfh cells59.8%24 h after 80 ng GFP-saRNA per 50,000 cells · Selected as the lead dose with minimal cytotoxicityMain text, printed p. 592 / PDF p. 5; Supplementary Figure S1H,I

Literature-reportedHydrodynamic diameter107.0 ± 13.4 nmPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12

Literature-reportedPolydispersity index0.16 ± 0.05Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12

Literature-reportedZeta potential-1.9 ± 1.5 mVPost-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12

Literature-reportedsaRNA encapsulation efficiency85.28 ± 3.56%Post-formulation characterization · UFC-TLNPSupplementary Table S2, SI PDF p. 12

Additional reported findings

CAR and Foxp3 coexpression

UFC-TLNP produced a reported 59.0% CAR-positive and Foxp3-positive Tfh-cell population.

Tfh cells; UFC-saRNA; in vitro · Main Figure 2B, PDF p. 4

Targeted regulatory-phenotype persistence

After UFC-RLNP treatment, the reported Foxp3-positive Tfh fractions were 60.6% on day 1, 56.4% on day 3, 51.9% on day 7 and 49.2% on day 14.

CXCR5-antibody-functionalized RLNP; n=3; in vitro · Main Figure 3B,C, PDF p. 6

Tfh versus conventional T-cell expression

At 24 h, UFC-RLNP produced 61.3% DeltaLNGFR-positive Tfh cells versus 1.44% conventional T cells in the reported assay.

Tfh-restricted UFC-saRNA translation plus CXCR5-targeted uptake; n=3 · Main Figure 3I,J

Preclinical autoimmune-hepatitis study

A single UFC-Tw/RLNP dose improved reported biochemical, immune and liver-histology endpoints in both prophylactic and established Ad-2D6 autoimmune-hepatitis-II mouse experiments relative to saline controls.

Female C57BL/6J mice; 5 micrograms saRNA IV on day 1 or day 28; preclinical evidence only · Main Figures 6-7 and Supplementary Figures S6-S7

Reported experimental tolerability

The authors reported no detectable red-blood-cell lysis in the tested assay, no significant Tfh cytotoxicity at tested in vitro doses, stable body weight and no treatment-associated abnormality in examined major-organ H&E sections.

Assay- and mouse-study-specific observations; not a formal toxicology program · Main Figure 2M; Supplementary Figures S1, S2G, S6A and S7G

Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.

The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.

Cited literature for this formulation and performance datasetZheng Z, Liu Y, Wang G, et al. In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis. Cell Stem Cell. 2026;33:589-604. DOI: 10.1016/j.stem.2026.02.006
Structure and lead selection: main Figure 1 and Supplementary Figure S1; base formulation: main text and Supplementary Table S1; preparation: STAR Methods; particle properties: Supplementary Table S2; targeted CAR-Tfh performance and mouse AIH-II studies: main Figures 2-7 and Supplementary Figures S2-S7.

Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Mass = concentration × volume × molecular weight

MassConcentrationVolumeMolecular weightg/mol

Enter any three values to calculate the fourth.

C₁V₁ = C₂V₂

C₁mMV₁mLC₂mMV₂mL

Enter any three values to calculate the fourth.

Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass	1 mM	5 mM	10 mM
10 mg	15.6477 mL	3.1295 mL	1.5648 mL
25 mg	39.1193 mL	7.8239 mL	3.9119 mL
50 mg	78.2387 mL	15.6477 mL	7.8239 mL
100 mg	156.4774 mL	31.2955 mL	15.6477 mL
250 mg	391.1935 mL	78.2387 mL	39.1193 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?

We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.

Pure lipid or solution — which should I choose?

Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.

How should I measure a small amount of oily or viscous lipid?

Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.

Can you support formulation optimization and scale-up?

Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.

Lipid Trp-L1-T4

Pack size & price

Description & Application

Recommended Products

113-AA-C8C14

ORNA Lipid AX-6

Lipid 10a-26

E10i-494

C14-4

Lipid 119-23

Acid-degradable Anionic Lipid (ADA)

DMA4-H228

Lipid H5T5

Lipid 11-A-M